Clinical Trials Browser

Phase 1/2 × Infliximab × 1 year × Clear all

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT02638701 2025-07-08

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Phase 1/2 Recruiting

Aneurysm, Vasculitis, Stroke